Evidence map›Paper›PMID 16082570›Full record

ArticlePediatric cardiology

Plasmatic [corrected] factor XIII reduces severe pleural effusion in children after open-heart surgery.

M Schroth, U Meißner, R Cesnjevar, M Weyand, H Singer, W Rascher, J Klinge

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Pediatric cardiology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Factor XIII-A: An Indispensable "Factor" in Haemostasis and Wound Healing.International journal of molecular sciences · 2021
    Review
  2. Article
  3. Article
  4. Usefulness of lymphography and computed tomography for detecting the site of chyle leakage.Indian journal of thoracic and cardiovascular surgery · 2019
    Article
  5. Article
  6. Article
  7. Roles of transglutaminases in cardiac and vascular diseases.Frontiers in bioscience : a journal and virtual library · 2007
    Review
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

M SchrothDepartment of Pediatrics, Friedrich-Alexander-University Erlangen-Nuremberg, Loschgestrasse 15, Erlangen, D-91054, Germany. michael.schroth@kinder.imed.uni-erlangen.de.
U MeißnerDepartment of Pediatrics, Friedrich-Alexander-University Erlangen-Nuremberg, Loschgestrasse 15, Erlangen, D-91054, Germany.
R CesnjevarDepartment of Cardiac Surgery, Friedrich-Alexander-University Erlangen-Nuremberg, Loschgestrasse 15, Erlangen, D-91054, Germany.
M WeyandDepartment of Cardiac Surgery, Friedrich-Alexander-University Erlangen-Nuremberg, Loschgestrasse 15, Erlangen, D-91054, Germany.
H SingerDepartment of Pediatrics, Friedrich-Alexander-University Erlangen-Nuremberg, Loschgestrasse 15, Erlangen, D-91054, Germany.
W RascherDepartment of Pediatrics, Friedrich-Alexander-University Erlangen-Nuremberg, Loschgestrasse 15, Erlangen, D-91054, Germany.
J KlingeDepartment of Pediatrics, Friedrich-Alexander-University Erlangen-Nuremberg, Loschgestrasse 15, Erlangen, D-91054, Germany.
Friedrich-Alexander-Universität Erlangen-Nürnberg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chylous effusions frequently occur after cardiac surgery due to severe damage to the lymphatic system, thus indicating that the insertion of a chest tube may be necessary. Factor XIII (FXIII) is discussed as being essential for wound healing. The aim of this retrospective study was to evaluate whether the application of a single dose of FXIII results in a reduced amount of pleural effusion, leading to an earlier release of patients from the hospital. The cases of 40 children with severe chylous effusions after open-heart surgery were examined. Twenty patients received FXIII and were compared to 20 age- and weight-matched patients who did not receive FXIII. Major parameters included the amount of effusion before and 1 and 3 days after the application of FXIII; the duration of chest tubes; the total amount of fluid loss via drainage; and the period of hospitalization. FXIII levels in plasma showed an inverse correlation with fluid loss. After application of a single dose of FXIII, a significant reduction of pleural effusion within the first 24 hours was detected. However, no difference was observed between the two groups when comparing the total amount of pleural effusions within the first 72 hours. Finally, the duration of hospitalization did not differ between the FXIII-treated and the control group. A single application of FXIII rapidly reduces the amount of chylous effusions in the early period after open-heart surgery. This effect is detectable only for 24 hours after the treatment and does not alter the further clinical outcome. Prospective clinical trials are warranted to determine if repeated application or a higher dose of FXIII may improve the clinical outcome of chylous leakages in children after open-heart surgery.

Indexed as

Case-Control StudiesChest TubesChildChild, PreschoolChylothoraxDose-Response Relationship, DrugDrug Administration ScheduleFactor XIIIFemaleHeart Defects, CongenitalHumansInfantLength of StayMalePleural EffusionPostoperative ComplicationsFactor XIII

Identifiers

PMID16082570
OpenAlexW2027438246

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.